Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million
Further diversifies Royalty Pharma's portfolio with market-leading respiratory therapyExpected to significantly add to long-term Adjusted Cash Receipts growth(1) (non-GAAP) NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has agreed to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from Theravance Biopharma, Inc. (NASDAQ:TBPH) and Innoviva, Inc. (NASDAQ:INVA) for $1.31 billion in cash up front and up to $300 million in additional payments contingent on the achievement of certain sales milestones. The acquisition is expected to close within ten business days. Trelegy, marketed by GSK, is a combination of an inhaled corticosteroi
